Entest BioMedical, Inc. Announces the Addition of New Chief Financial Officer to Management Team

Entest BioMedical, Inc. Announces the Addition of New Chief Financial Officer to Management Team
 
New CFO Comes to Entest From SAIC Having a Strong Background in M&A Accounting and Financial Reporting; Blogcast on Expansion of Management Team Wednesday, April 7, 2010 11:00 am PDT -- www.entestbioblog.com/live
April 07, 2010: 10:41 AM ET


Entest BioMedical, Inc. (OTCBB: ENTB) announced that it has hired Tammy Reynolds, CPA as Its new Chief Financial Officer. Ms. Reynolds joins Entest BioMedical from Science Applications International Corporation (SAIC).

Ms. Reynolds has an extensive background in mergers & acquisitions accounting, financial reporting, tax accounting, budgeting / forecasting and fixed asset reconciliation. Prior to working for SAIC, she was a senior accountant with Bruno Skorheim, LLP where she worked with corporate clients in the areas of financial reporting and tax compliance. Ms. Reynolds holds a Bachelor of Science degree in accounting from San Diego State University and is an active certified public accountant (CPA), participating in numerous accounting associations.

Dr. David Koos, Chairman & CEO of Entest BioMedical, stated, "We are extremely fortunate to have Ms. Reynolds join the management team. She is an exceptional professional. We feel her strong analytic skills will help us in forecasting our future cost factors as we grow Entest."

The Company's scheduled blogcast will address the building of Its management team, areas the Company into which the Company seeks to expand, and the significance of the addition of a new CFO. Interested parties can listen to the blogcast at www.entestbioblog.com/live on Wednesday April 7, 2010 at 11:00 a.m. PDT.

About Entest BioMedical Inc.:
Entest BioMedical Inc. (OTCBB: ENTB) is involved with the development of stem cell therapy treatments for Chronic Obstructive Pulmonary Disease (COPD), immuno-cancer therapies, testing procedures for diabetes, stem cell research applications for diabetes and other illnesses. The Company also is involved with medical device development (including stem cell extraction instrumentation). ENT-576TM is a proprietary laser device currently under development by Entest. The Company has filed 4 patent applications relating to the treatment of COPD. Entest BioMedical Inc. is a majority owned subsidiary of Bio-Matrix Scientific Group Inc. (OTCBB: BMSN). Recently Entest announced publication of its platform technology in the peer-reviewed Journal of Translational Medicine which is available at http://www.translational-medicine.com/content/8/1/16. For additional information on Entest, go to the Company's website: www.entestbio.com or its blog site: www.entestbioblog.com.

Disclaimer
This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.

Contact:
David R. Koos, Chairman & CEO
Entest BioMedical Inc.
619.702.1404 Direct
619.330.2328 Fax
www.entestbio.com
[email protected]
Donald C. Weinberger
Adam Lowensteiner
Wolfe Axelrod Weinberger Assoc. LLC
Tel. (212) 370-4500
Fax (212) 370- 4505

 

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.